The enlarged bench of the Full Court of the Australian Federal Court has clarified what constitutes infringement of Swiss-style claims in Mylan Health Pty Ltd v Sun Pharma ANZ...
First published as: Pearce et al, 'New Thinking for New Science - Biopharmaceutical Patent Disputes in Australia' (2020) 120 Intellectual Property Forum 33. As we consider the...
Significant biosimilar activities this week include June 20 | The NZ Herald reported a new study by NZ scientists which indicates that transgenic goats are capable of producing...
We all know the story. Three little pigs leave home to seek their fortunes, and make houses out of either straw, sticks or bricks. Every child knows that the brother pigs who...
Boutique specialist patent firm Pearce IP is proud to report a strong presence in the prestigious IAM Patent 1000 ranking of the world's top patent professionals for 2020....
Significant biosimilar activities this week include 08 Jun 20 | The Centre for Biosimilars reported that the WHO certified Celltrion's Truxima® (rituximab) in its...
Significant biosimilar activities this week include 29 May 20 | In a filing to the Securities and Exchange Commission, Alexion announced it has settled its eculizumab dispute...
Significant biosimilar activities this week include 25 May 20 | The American Journal of Managed Care reported two cost savings studies presented at a virtual meeting of the...
Boutique specialist firm Pearce IP is delighted to announce the appointment of biotech/pharma IP leader Jacinta Flattery-O'Brien PhD as Special Counsel. A highly regarded patent...
Significant biosimilar activities this week include 11 May 20 | AstraZeneca announced it had recovered the global rights to brazikumab from Amgen. AstraZeneca had previously...
Significant biosimilar activities this week include 11 May 20 | Healio reported on a new study comparing faricimab to ranibizumab which was presented at a virtual meeting of the...
Significant biosimilar activities this week include 01 May 2020 | AbbVie released its Q1 2020 financial results, reporting a 13.7% increase in US sales of Humira® (adalimumab)...
Significant biosimilar activities this week include 23 April 2020 | Henlius Biotech announced it has received two EU GMP certificates related to its trastuzumab biosimilar HLX02....
Significant biosimilar activities this week include 21 Apr 20 | The Centre for Biosimilars reported that Xbrane Pharma was continuing clinical trials of its ranibizumab candidate...
Significant biosimilar activities this week include 14 April 20 | Mylan and Biocon launched Fulphila® (pegfilgrastim) in Australia. Fulphila® is indicated for the treatment of...
Significant biosimilar activities this week include March 20 | BiosanaPharma released the results of Ph I trials of BP001 (omalizumab), reporting comparability to Xolair®. 06...
Significant biosimilar activities this week include 30 Mar 20 | Biocad announced it had received registration certificates from Bosnia and Herzegovina for Acellbia® (rituximab)...
Significant biosimilar activities this week include March 20 | The UK High Court ruled filing errors in a Supplementary Protection Certificate (SPC) for Lucentis®...
Significant biosimilar activities this week include 16 Mar 20 | Teva and Celltrion launched Herzuma (trastuzumab) in the US. Herzuma is indicated for the treatment of breast...
Significant biosimilar activities this week include 09 Mar 20 | The FDA and FTC held a public workshop to further their efforts in creating a better biosimilar landscape in the...
Significant biosimilar activities this week include 02 Mar 20 | Celltrion launched Remsima SC, its subcutaneous infliximab product, in the UK. To support the launch,...
Significant biosimilar activities this week include 24 Feb 20 | The FDA launched a searchable version of the 'Purple Book', containing information about FDA licensed biological...
As we previously foreshadowed, the innovation patent system has been given its end dates: 25 August 2021: last date to lodge innovation patents; and 25 August 2029: date on which...
Significant biosimilar activities this week include 12 Feb 20 | Wockhardt announced divestment of assets to Dr Reddy's, under which 62 products and a manufacturing facility will...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
